Aggressive cutaneous T-cell lymphomas after TNFα blockade

Amy E. Adams, Jeffrey Zwicker, Clara N Curiel, Marshall E. Kadin, Kenneth R. Falchuk, Reed Drews, Thomas S. Kupper

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Pharmacologic blockade of TNFα has been a highly effective approach to treating several immunologically mediated diseases, including rheumatoid arthritis, Crohn's disease, and psoriatic arthritis.1,2,3 Both etanercept, the recombinant extracellular domain of the tumor necrosis factor receptor 2 (TNFR2), and infliximab, a humanized murine antibody, bind TNFα and block its interaction with cell surface receptors. Recently, it has become clear that blockade of TNFα action is profoundly immunosuppressive, and may result in reactivation of tuberculosis and histoplasmosis, as well as the emergence of B-cell lymphomas.4,5,6 In this report, we describe two cases of cutaneous and systemic T-cell lymphoma that progressed rapidly in the setting of TNFα blockade. Both cases were characterized by rapid onset, a fulminant clinical course with extensive cutaneous and systemic involvement, and death within months of diagnosis.

Original languageEnglish (US)
Pages (from-to)660-662
Number of pages3
JournalJournal of the American Academy of Dermatology
Volume51
Issue number4
DOIs
StatePublished - Oct 2004
Externally publishedYes

Fingerprint

Receptors, Tumor Necrosis Factor, Type II
Antibodies, Monoclonal, Humanized
Cutaneous T-Cell Lymphoma
Histoplasmosis
Cell Surface Receptors
Immunosuppressive Agents
Crohn Disease
Rheumatoid Arthritis
Tuberculosis
B-Lymphocytes
Skin
Etanercept
Infliximab

ASJC Scopus subject areas

  • Dermatology

Cite this

Adams, A. E., Zwicker, J., Curiel, C. N., Kadin, M. E., Falchuk, K. R., Drews, R., & Kupper, T. S. (2004). Aggressive cutaneous T-cell lymphomas after TNFα blockade. Journal of the American Academy of Dermatology, 51(4), 660-662. https://doi.org/10.1016/j.jaad.2004.03.047

Aggressive cutaneous T-cell lymphomas after TNFα blockade. / Adams, Amy E.; Zwicker, Jeffrey; Curiel, Clara N; Kadin, Marshall E.; Falchuk, Kenneth R.; Drews, Reed; Kupper, Thomas S.

In: Journal of the American Academy of Dermatology, Vol. 51, No. 4, 10.2004, p. 660-662.

Research output: Contribution to journalArticle

Adams, AE, Zwicker, J, Curiel, CN, Kadin, ME, Falchuk, KR, Drews, R & Kupper, TS 2004, 'Aggressive cutaneous T-cell lymphomas after TNFα blockade', Journal of the American Academy of Dermatology, vol. 51, no. 4, pp. 660-662. https://doi.org/10.1016/j.jaad.2004.03.047
Adams, Amy E. ; Zwicker, Jeffrey ; Curiel, Clara N ; Kadin, Marshall E. ; Falchuk, Kenneth R. ; Drews, Reed ; Kupper, Thomas S. / Aggressive cutaneous T-cell lymphomas after TNFα blockade. In: Journal of the American Academy of Dermatology. 2004 ; Vol. 51, No. 4. pp. 660-662.
@article{61b49d327f7c48a1a5076941fa25ad1c,
title = "Aggressive cutaneous T-cell lymphomas after TNFα blockade",
abstract = "Pharmacologic blockade of TNFα has been a highly effective approach to treating several immunologically mediated diseases, including rheumatoid arthritis, Crohn's disease, and psoriatic arthritis.1,2,3 Both etanercept, the recombinant extracellular domain of the tumor necrosis factor receptor 2 (TNFR2), and infliximab, a humanized murine antibody, bind TNFα and block its interaction with cell surface receptors. Recently, it has become clear that blockade of TNFα action is profoundly immunosuppressive, and may result in reactivation of tuberculosis and histoplasmosis, as well as the emergence of B-cell lymphomas.4,5,6 In this report, we describe two cases of cutaneous and systemic T-cell lymphoma that progressed rapidly in the setting of TNFα blockade. Both cases were characterized by rapid onset, a fulminant clinical course with extensive cutaneous and systemic involvement, and death within months of diagnosis.",
author = "Adams, {Amy E.} and Jeffrey Zwicker and Curiel, {Clara N} and Kadin, {Marshall E.} and Falchuk, {Kenneth R.} and Reed Drews and Kupper, {Thomas S.}",
year = "2004",
month = "10",
doi = "10.1016/j.jaad.2004.03.047",
language = "English (US)",
volume = "51",
pages = "660--662",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Aggressive cutaneous T-cell lymphomas after TNFα blockade

AU - Adams, Amy E.

AU - Zwicker, Jeffrey

AU - Curiel, Clara N

AU - Kadin, Marshall E.

AU - Falchuk, Kenneth R.

AU - Drews, Reed

AU - Kupper, Thomas S.

PY - 2004/10

Y1 - 2004/10

N2 - Pharmacologic blockade of TNFα has been a highly effective approach to treating several immunologically mediated diseases, including rheumatoid arthritis, Crohn's disease, and psoriatic arthritis.1,2,3 Both etanercept, the recombinant extracellular domain of the tumor necrosis factor receptor 2 (TNFR2), and infliximab, a humanized murine antibody, bind TNFα and block its interaction with cell surface receptors. Recently, it has become clear that blockade of TNFα action is profoundly immunosuppressive, and may result in reactivation of tuberculosis and histoplasmosis, as well as the emergence of B-cell lymphomas.4,5,6 In this report, we describe two cases of cutaneous and systemic T-cell lymphoma that progressed rapidly in the setting of TNFα blockade. Both cases were characterized by rapid onset, a fulminant clinical course with extensive cutaneous and systemic involvement, and death within months of diagnosis.

AB - Pharmacologic blockade of TNFα has been a highly effective approach to treating several immunologically mediated diseases, including rheumatoid arthritis, Crohn's disease, and psoriatic arthritis.1,2,3 Both etanercept, the recombinant extracellular domain of the tumor necrosis factor receptor 2 (TNFR2), and infliximab, a humanized murine antibody, bind TNFα and block its interaction with cell surface receptors. Recently, it has become clear that blockade of TNFα action is profoundly immunosuppressive, and may result in reactivation of tuberculosis and histoplasmosis, as well as the emergence of B-cell lymphomas.4,5,6 In this report, we describe two cases of cutaneous and systemic T-cell lymphoma that progressed rapidly in the setting of TNFα blockade. Both cases were characterized by rapid onset, a fulminant clinical course with extensive cutaneous and systemic involvement, and death within months of diagnosis.

UR - http://www.scopus.com/inward/record.url?scp=4644241313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644241313&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2004.03.047

DO - 10.1016/j.jaad.2004.03.047

M3 - Article

VL - 51

SP - 660

EP - 662

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 4

ER -